1. Academic Validation
  2. Phytochemical characterization and multi-target mechanism of Gleditsia sinensis Fructus in lung adenocarcinoma treatment

Phytochemical characterization and multi-target mechanism of Gleditsia sinensis Fructus in lung adenocarcinoma treatment

  • Naunyn Schmiedebergs Arch Pharmacol. 2025 Oct 29. doi: 10.1007/s00210-025-04766-9.
Zhengyuan Fan 1 2 3 Di Han 1 2 3 Tingting Shen 1 2 3 Ya Li 1 2 3 Suxiao Liu 1 Suyun Li 4 5
Affiliations

Affiliations

  • 1 Chinese Medicine Pharmacology (Respiratory) Laboratory, Henan Key Laboratory of Chinese Medicine for Respiratory Disease, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, 450008, China.
  • 2 Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Henan University of Chinese Medicine, No.19 Renmin Road, Zhengzhou, 450000, Henan, China.
  • 3 Co-Construction Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases By Henan & Education Ministry of P.R. China, Henan University of Chinese Medicine, Zhengzhou, 450046, China.
  • 4 Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Henan University of Chinese Medicine, No.19 Renmin Road, Zhengzhou, 450000, Henan, China. suyunli@hactcm.edu.cn.
  • 5 Co-Construction Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases By Henan & Education Ministry of P.R. China, Henan University of Chinese Medicine, Zhengzhou, 450046, China. suyunli@hactcm.edu.cn.
Abstract

Gleditsia sinensis Fructus (GSF) exhibits anti-cancer activity and is effective against lung adenocarcinoma (LUAD). However, its underlying mechanisms remain unclear. In this study, the potential chemical components, targets, and pathways of GSF in treating LUAD were investigated using UHPLC-HRMS combined with network pharmacology analysis. These findings were subsequently verified via molecular docking, molecular dynamics simulation, and in vitro cell experiments. The results showed that a total of 61 components targeting 192 LUAD-related genes were identified, and 177 candidate targets of GSF against LUAD were obtained, among which Akt1, Src, EGFR, IL6, and TNF may be the core targets. Enrichment analysis revealed that the mechanisms were related to various cancer-related pathways, particularly the PI3K-AKT signaling pathway. Molecular docking demonstrated that the active components of GSF, particularly luteolin, exhibited excellent binding affinity to the top five core targets. Molecular dynamics simulation results showed a similar trend. Therefore, we identified luteolin as the primary active component of GSF. The cell experiments revealed that luteolin significantly inhibited cell growth and proliferation and promoted the Apoptosis of A549 cells, exhibiting effects similar to those of cisplatin. In addition, luteolin significantly upregulated the expression of Bax and cleaved-caspase3 and decreased the expression of P-AKT and BCL2. Our results demonstrate that GSF can exert anti-LUAD effects through multi-components, multi-targets, and multi-pathways. Luteolin, one of the main active components of GSF, suppressed proliferation and induced Apoptosis in A549 cells, possibly through inhibiting the Akt signaling pathway.

Keywords

A549; Lung cancer; Luteolin; Molecular docking; Molecular dynamics simulation; Network pharmacology.

Figures
Products